Skip to main navigation
  • About
    • Our Mission
    • Core Values
    • Leadership
    • Partners
  • CRISPR/Cas9
    • What’s CRISPR/Cas9?
    • How CRISPR/Cas9 Works
    • Types of Edits
    • Glossary
  • Programs & Pipelines
    • Full-Spectrum Approach
    • Our Pipeline
    • In Vivo Therapies
    • Ex Vivo Therapies
  • Patients & Families
    • Our Commitment
    • Clinical Trials
    • Community Perspectives & Resources
    • Expanded Access Policy
  • Healthcare Professionals
  • Investors & Media
    • Overview
    • Press Releases
    • Scientific Publications & Presentations
    • Corporate Deck
    • Events & Presentations
    • Press Kit
    • Corporate Governance
    • Financial Info
    • Stock Info
    • Analyst Coverage
    • Investor Resources
  • Careers
    • Life @ Intellia
    • Join Us
  • Full-Spectrum Blog
  • Contact
logo
  • Full-Spectrum Blog
  • Contact
  • About
    • Our Mission
    • Core Values
    • Leadership
    • Partners
  • CRISPR/Cas9
    • What’s CRISPR/Cas9?
    • How CRISPR/Cas9 Works
    • Types of Edits
    • Glossary
  • Programs & Pipelines
    • Full-Spectrum Approach
    • Pipeline
    • In Vivo Therapies
    • Ex Vivo Therapies
  • Patients & Families
    • Our Commitment
    • Clinical Trials
    • Community Perspectives & Resources
    • Expanded Access Policy
  • Healthcare Professionals
  • Investors & Media
    • Overview
    • Press Releases
    • Scientific Publications & Presentations
    • Corporate Deck
    • Events & Presentations
    • Press Kit
    • Corporate Governance
    • Financial Info
    • Stock Info
    • Analyst Coverage
    • Investor Resources
  • Careers
    • Life @ Intellia
    • Join Us
Investors & Media

Investors & Media

Investor Relations

  • Overview
  • Press Releases
  • Scientific Publications & Presentations
  • Corporate Deck
  • Events & Presentations
  • Press Kit
  • Corporate Governance
  • Financial Info
  • Stock Info
  • Analyst Coverage
  • Investor Resources

Stock Information

  

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases
Jun 24, 2022
Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose
Read More
Events & Presentations
More events are coming soon.
Contact IR Contact IR
Email Alerts
RSS Feeds
RSS Feeds
Print Page

Footer Links

  • Cookie Policy
  • Terms of Use
  • Privacy Policy

© Intellia Therapeutics, Inc. 2022

Intellia Therapeutics and the Intellia Therapeutics logo are registered trademarks with the U.S. Patent & Trademark Office.